UK Markets closed

Evotec AG (EVT.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
41.55-0.88 (-2.07%)
At close: 5:35PM CEST
Full screen
Previous close42.43
Open42.59
Bid41.53 x 105300
Ask41.56 x 169300
Day's range41.30 - 42.85
52-week range22.47 - 45.83
Volume478,034
Avg. volume364,725
Market cap6.838B
Beta (5Y monthly)0.87
PE ratio (TTM)156.20
EPS (TTM)0.27
Earnings date11 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Evotec SE files registration statement for proposed offering of American Depositary Shares

    DGAP-News: Evotec SE / Key word(s): Miscellaneous11.10.2021 / 07:30 The issuer is solely responsible for the content of this announcement.Hamburg, Germany, 11 October 2021:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed offering and sale in the United States of shares of Evotec represented by American Depositary Shares (

  • EQS Group

    Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type

    DGAP-News: Evotec SE / Key word(s): Miscellaneous08.10.2021 / 07:30 The issuer is solely responsible for the content of this announcement. INCLUDES NEW CELL TYPES FOR STUDYING MOLECULAR DISEASE SIGNATURES FOR DISCOVERY OF DISEASE-MODIFYING THERAPIES FOR NEURODEGENERATIVE DISEASES TRIGGERS US$ 9.0 M PAYMENT TO EVOTECHamburg, Germany, 08 October 2021:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its collaboration with Bristol Myers Squibb (NYSE: BM

  • EQS Group

    Just - Evotec Biologics opens J.POD 1 US in Redmond, Washington

    DGAP-News: Evotec SE / Key word(s): Miscellaneous11.08.2021 / 07:30 The issuer is solely responsible for the content of this announcement. J.POD(R) 1 US PROVIDES UNIQUELY FLEXIBLE CGMP MANUFACTURING OF KILOGRAMS TO METRIC TONS OF BIOLOGICS THERAPEUTICS J.POD(R) FACILITY EXPANDS JUST - EVOTEC BIOLOGICS' CAPABILITIES INTO COMMERCIAL BIOLOGICS MANUFACTURING AND ADDS LATE STAGE CLINICAL DEVELOPMENT AND COMMERCIAL SUPPLY FOR BOTH SMALL AND LARGE QUANTITIES OF DRUG SUBSTANCEHamburg, Germany, 11 August